Adjuvant treatment with osimertinib in patients with stage IB-IIIA EGFR-positive NSCLC after complete tumor resection reduces the risk of relapse and death by 83%
Get access
If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.
